CURIS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.36 USD | -2.54% |
|
-7.50% | -18.75% |
| May. 14 | Transcript : Curis, Inc. - Special Call | |
| May. 14 | Curis, Inc. Announces Additional Data from Take Aim Leukemia Study | CI |
Financials (USD)
| Sales 2024 * | 8.78M | Sales 2025 * | 8.8M | Capitalization | 61.06M |
|---|---|---|---|---|---|
| Net income 2024 * | -48M | Net income 2025 * | -53M | EV / Sales 2024 * | 6.95 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 6.94 x |
| P/E ratio 2024 * |
-1.68
x | P/E ratio 2025 * |
-2.25
x | Employees | 49 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.82% |
More Fundamentals
* Assessed data
More news
Latest transcript on Curis, Inc.
More recommendations
More press releases
| 1 day | -2.54% | ||
| 1 week | -7.50% | ||
| 1 month | -32.51% | ||
| 3 months | +1.67% | ||
| 6 months | -27.60% | ||
| Current year | -18.75% |
1 week
10.14
11.46
1 month
9.5016.99
Current year
8.2417.49
1 year
3.8018.00
3 years
3.80312.00
5 years
3.80348.00
10 years
3.80375.00
| Managers | Title | Age | Since |
|---|---|---|---|
James Dentzer
CEO | Chief Executive Officer | 57 | 16-03-28 |
Diantha Duvall
DFI | Director of Finance/CFO | 52 | 22-07-25 |
| Chief Tech/Sci/R&D Officer | - | 22-01-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kenneth Kaitin
BRD | Director/Board Member | 71 | 03-10-31 |
Martyn Greenacre
CHM | Chairman | 82 | 00-02-13 |
James Dentzer
CEO | Chief Executive Officer | 57 | 16-03-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.01% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 10.36 | -2.54% | 28,724 |
| 24-05-30 | 10.63 | +0.28% | 12,906 |
| 24-05-29 | 10.6 | -5.10% | 16,989 |
| 24-05-28 | 11.17 | -0.27% | 33,473 |
| 24-05-24 | 11.2 | +0.54% | 8,163 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
10.36
USD
Average target price
78
USD
Spread / Average Target
+652.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.75% | 61.06M | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- CRIS Stock
